Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Bicycle Therapeutics (BCYC) · oqro.io/stocks/BCYC · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Bicycle Therapeutics insider trading
Have Bicycle Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Bicycle Therapeutics was filed in the last 90 days. The latest on record was on Dec 17, 2024.
How often do Bicycle Therapeutics insiders buy and sell shares?
Since 2019, Bicycle Therapeutics insiders reported 21 open-market purchases and 199 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2024.
Who is selling Bicycle Therapeutics stock?
In the last 90 days, 6 insiders of Bicycle Therapeutics (BCYC) reported 11 open-market sales worth $59K in total on SEC Form 4. The largest seller by value was Kevin Lee, with $27K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade BCYC?
No trade in Bicycle Therapeutics (BCYC) was disclosed by a member of Congress in the last 12 months.
When does Bicycle Therapeutics report its next results?
Bicycle Therapeutics's next results are expected on Mar 15, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−53.0% (−$3.27) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $6.17 on Nov 20, 2025 to $2.90 on Nov 20, 2026 (−53.0%). Disclosed in this range: 0 insider trades, 11 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
$2$4$5$6$7$8$2.90
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 11 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Cambridge, X0.
Last 12 months
−53.0%
S&P 500 +5.7% over the same dates
Market value
$203M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.86M shares sold short (5.5% of shares outstanding), +11.8% vs the previous count, 8.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$34.1M
+190.2% vs the same quarter a year earlier
Free cash flow, last 12 months
−$177M
This quarter −$40.6M, a year earlier −$71.8M
Net debt
—
Debt —, cash $470M, at Sep 30, 2026
Net income, last 12 months
−$142M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 29, 2026.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 11,000 words.
From “Overview”, in the company's words
We are a clinical-stage pharmaceutical company developing a novel class of medicines, which we refer to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. Bicycle molecules are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic, or PK, properties of a small molecule.
What the section covers (28 headings)
Overview
Workforce Reductions
Financial Overview
Components of Our Results of Operations
Collaboration Revenue
Expenses
Research and Development Expenses
General and Administrative Expenses
Other Income (Expense)
Interest and Other Income
Interest Expense
Loss on Extinguishment of Debt
Gain on Extinguishment of Research and Development Funding Liability
Provision For (Benefit From) Income Taxes
And 14 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 17, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 42.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (11.8% on ATS, 30.9% with other brokers), close to its 26-week average of 43.6%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (17.2%), IBKR ATS (12.2%), INSTINCT X (11.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Mar 17, 2026, compared with the one filed Feb 25, 2025. Read the filing
New risk factors in the latest annual report (3 headings)
Changes in the regulatory landscape, policies, or processes, as well as disruptions at the FDA and other government agencies caused by layoffs, changes in personnel, funding shortages or global health concerns could negatively impact our business.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
Our recent workforce reductions were undertaken to significantly reduce our ongoing operating expenses, but they may not result in our intended outcomes and may yield unintended consequences and additional costs.
No longer listed (2 headings from the year before)
The withdrawal of the U.K. from the EU, commonly referred to as “Brexit,” may adversely impact our ability to obtain regulatory approvals of our product candidates in the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.
If we are a controlled foreign corporation, there could be adverse U.S. federal income tax consequences to certain U.S. holders.
Legal proceedings (Item 3)
From time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We are not currently subject to any material legal proceedings.
Source: SEC EDGAR, Form 10-K filed Mar 17, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
1 certified in FY2026 Q3, vs 0 a year earlier. 1 position in total, median offered wage $193K a year.
Senior Manager, Data Science · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Bicycle Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 11 open-market sales (about $59K, in 6 filings, by 6 people). One Form 4 can list many transactions. In the 12 months before that, they filed 10 open-market purchases (about $21.2M, in 1 filing) and 37 open-market sales (about $710K, in 20 filings). (Bicycle Therapeutics on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 0 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for BCYC on the settlement date of Oct 30, 2026 was 3,858,686 shares (+11.75% on the previous report), about 8.38 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Sculptor Capital LP (new position); Pinnacle Associates Ltd (increased, 4,580 shares); the largest that shrank: Silvercrest Asset Management Group LLC (sold out); Siren, L.L.C. (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Bicycle Therapeutics filed a Form 8-K on Aug 20, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member. The company's own opening sentence of that report reads: "On August 18, 2026, Charles Swanton resigned as a Class II director of the Board of Directors (the 'Board') of Bicycle Therapeutics plc (the 'Company'), as a member of the Board’s committees and as a member of the Company’s Clini..."
Who holds it. 104 funds reported a stake in Bicycle Therapeutics in their 13F for Q2 2026. The largest by value: BAKER BROS. ADVISORS LP (29.1% of the value reported), FCPM III SERVICES B.V. (9.3% of the value reported), ARMISTICE CAPITAL, LLC (9.1% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Bicycle Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 11 open-market sales (about $59K, in 6 filings, by 6 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 10 open-market purchases (about $21.2M, in 1 filing) and 37 open-market sales (about $710K, in 20 filings).
The largest sale: Kevin Lee, CHIEF EXECUTIVE OFFICER, about $21K, filed Oct 7, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 0 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for BCYC on the settlement date of Oct 30, 2026 was 3,858,686 shares (+11.75% on the previous report), about 8.38 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Sculptor Capital LP (new position); Pinnacle Associates Ltd (increased, 4,580 shares); the largest that shrank: Silvercrest Asset Management Group LLC (sold out); Siren, L.L.C. (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $6.34M for its principal executive officer, and an average of $2.31M for the other named executive officers.
Company reports, price and press
Bicycle Therapeutics filed a Form 8-K on Aug 20, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On August 18, 2026, Charles Swanton resigned as a Class II director of the Board of Directors (the 'Board') of Bicycle Therapeutics plc (the 'Company'), as a member of the Board’s committees and as a member of the Company’s Clini..."
Insiders of Bicycle Therapeutics reported 21 open-market purchases and 199 sales since 2019; purchases in 2 different years, most recently 2024.
Year
Bought
Sold
2026
—
$59K11×11 trades
2025
—
$710K37×37 trades
2024
$21.2M10×10 trades
$965K32×32 trades
Bicycle Therapeutics filed a Form 8-K on Mar 17, 2026 (Items 2.02, 5.02) that OQRO classes as: changed a top executive or board member, and reported its results.
The company's own opening sentence of that report reads: "On March 11, 2026, the Company’s Board of Directors appointed Jennifer Perry, Pharm.D. as Chief Operating Officer, effective as of March 17, 2026 (the 'Transition Date')."
Bicycle Therapeutics filed a Form 8-K on Feb 3, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On January 29, 2026, the Board of Directors (the ' Board ') of Bicycle Therapeutics plc (the ' Company ') appointed Travis Thompson as Chief Financial Officer, effective as of January 29, 2026 (the ' Transition Date ')."
Press coverage listed by Finnhub: "Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results" (Yahoo, Oct 29, 2026).
Press coverage listed by Finnhub: "Bicycle: 'Hold' On Zelenectide Deprioritization And Shift To EphA2+ Tumor Targeting" (SeekingAlpha, Aug 4, 2026).
Press coverage listed by Finnhub: "Bicycle Therapeutics: Trading Below Cash Amid Multiple Uncertainties" (SeekingAlpha, Jun 1, 2026).
BCYC closed at $3.11 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $3.54 to $3.11, a change of −12.0%.
Who holds it
104 funds reported a stake in Bicycle Therapeutics in their 13F for Q2 2026. The largest by value: BAKER BROS. ADVISORS LP (29.1% of the value reported), FCPM III SERVICES B.V. (9.3% of the value reported), ARMISTICE CAPITAL, LLC (9.1% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Since Nov 18, 2025, BCYC is down 55.2% and the index fund is up 4.5%: 60 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BCYC moves
A usual day
±2.1%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
6.8%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−7.6%Feb 3, 2026
Largest one-day rise
+18.6%Oct 5, 2026
Deepest fall of the year
−61.4%From the close of Dec 10, 2025 to Nov 20, 2026.
Days of 5% or more
28Out of 252 sessions, in either direction.
Beta 1.7(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
2023
—
$708K25×25 trades
2021
—
$26.4M86×86 trades
2020
—
$808K8×8 trades
2019
$45.9M11×11 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Oct 26, 2026
Insiders. In the 30 days to Oct 26, 2026, insiders filed 0 open-market purchases and 11 open-market sales (about $59K, in 6 filings, by 6 people). Bicycle Therapeutics on OQRO
3 more points, with the facts they come from, are in OQRO Pro.
after the market closes; the date can move until the company confirms it
Purchases after results
0%
0 of 10 insider purchases since 2019 came within 30 days after a results announcement
From Bicycle Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Bicycle Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.